Sosei Group Co. (OTCMKTS:SOLTF – Get Free Report) shares crossed below its two hundred day moving average during trading on Thursday . The stock has a two hundred day moving average of $16.24 and traded as low as $10.65. Sosei Group shares last traded at $10.65, with a volume of 300 shares.
Wall Street Analysts Forecast Growth
A number of equities research analysts have weighed in on the company. Jefferies Financial Group downgraded Sosei Group from a “buy” rating to an “underperform” rating in a research report on Tuesday, June 27th. Citigroup downgraded Sosei Group from a “buy” rating to a “sell” rating in a research report on Wednesday, June 28th.
Sosei Group Price Performance
Sosei Group Company Profile
Sosei Group Corporation develops biopharmaceutical products worldwide. Its marketed products include Ultibro/Breezhaler and Seebri/Breezhaler for the treatment of chronic obstructive pulmonary disease; Enerzair to treat asthma; and ORAVI, an oropharyngeal candidiasis. The company's product pipeline consists of GPR35 agonist, for inflammatory bowel disease/GI disorders, which is in preclinical stage; HTL0016878 for Schizophrenia and other neuropsychiatric disorders; PF-07081532 for Type 2 diabetes mellitus and obesity; PF-07054894 for inflammatory bowel disease; and PF-07258669 for anorexia.
- Five stocks we like better than Sosei Group
- Compound Interest and Why It Matters When Investing
- WeWork Stock Soars: Meme Stock Madness or Mirage?
- How to Use the MarketBeat Stock Split Calculator
- Shutterstock is the Value Stock they don’t want you to know about
- How to Most Effectively Use the MarketBeat Earnings Screener
- 3 Low-Cost ETFs That Are Crushing SPY
Receive News & Ratings for Sosei Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sosei Group and related companies with MarketBeat.com's FREE daily email newsletter.